Abstracts Archive - Page 116 of 2607 - ACR Meeting Abstracts

Abstract Number: 1404 • ACR Convergence 2025
Higher cardiovascular risk and lymphoma development in primary Sjögren’s Syndrome with extraglandular involvement
Teresa Blázquez Sánchez¹, Antía García Fernández¹, Jorge Mairal Monesma², Arantxa Torres Roselló³, Elena Heras Recuero⁴, Raquel Largo Carazo⁵, Juan Antonio Martínez López⁶ and Miguel A. González-Gay⁷, ¹Fundacion Jiménez Díaz, Madrid, Madrid, Spain, ²Instituto de Investigacion Fundación Jiménez Díaz, Madrid, Spain, ³Fundacion Jiménez Díaz, Madrid, Spain, ⁴Hospital Fundacion Jimenez Dias, Madrid, Spain, ⁵Instituto de Investigacion Fundacion Jiménez Díaz, Madrid, Spain, ⁶Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain, ⁷Department of Rheumatology and Joint and Bone Research Unit, Hospital Universitario Fundación Jiménez Díaz, and Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Madrid, Spain, and Medicine and Psychiatry Department, University of Cantabria, Santander, Spain
Background/Purpose: Primary Sjögren’s syndrome (pSS) can have a systemic involvement with extraglandular manifestations, which are associated with more severe disease and with higher risk of…
Abstract Number: 1262 • ACR Convergence 2025
Perspectives of Lupus Patients on Quality of Life Measures: A Qualitative Study
Cristina Arriens¹, Fredonna Carthen², Alexandre Cammarata-Mouchtouris¹, Judith James¹, Joan Merrill³ and Motolani Ogunsanya⁴, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma, OK, ³Oklahoma Medical Research Foundation, Oklahoma City ⁷³¹⁰⁴, OK, ⁴University of Oklahoma Health Sciences Center, Edmond, OK
Background/Purpose: Lupus has profound impact on physical, social, and emotional well-being. Health-related quality of life (HRQOL) measures are increasingly incorporated into lupus research and the…
Abstract Number: 1451 • ACR Convergence 2025
Bimekizumab was Efficacious Regardless of Age, BMI, CRP, or HLA-B27 Status: 1-Year Results from Two Phase 3 Studies
Marina Magrey¹, Helena Marzo-Ortega², Yuho Kadono³, David Nicholls⁴, Martin Rudwaleit⁵, Atul Deodhar⁶, Gaëlle Varkas⁷, Chetan Prajapati⁸, Sarah Kavanagh⁹ and Victoria Navarro-Compan¹⁰, ¹Case Western Reserve University School of Medicine/University Hospitals Cleveland, Richfield, OH, ²NIHR Leeds Biomedical Research Centre, The Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, United Kingdom, ³Department of Orthopaedic Surgery, Saitama Medical University, Saitama, ⁴Clinical Trials Unit, University of the Sunshine Coast, Queensland, Australia, ⁵Bielefeld University, Medical School and University Medical Centre OWL, Klinikum Bielefeld, Department of Rheumatology, Bielefeld, Germany, ⁶Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ⁷Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁸UCB, Slough, United Kingdom, ⁹UCB, Morrisville, NC, ¹⁰Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain
Background/Purpose: Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17F in addition to IL-17A, has shown efficacy to Week (Wk) 52 in patients…
Abstract Number: 1455 • ACR Convergence 2025
Sonelokimab in Patients With Active Psoriatic Arthritis Who Are Naive to Biologic DMARDs: Phase 2 ARGO Analysis and Phase 3 IZAR-1 Study Design
Philip J. Mease¹, Laure Gossec², Atul Deodhar³, Xenofon Baraliakos⁴, Frank Behrens⁵, Joseph F Merola⁶, Lihi Eder⁷, Ana-Maria Orbai⁸, Andreas Ramming⁹, Iain McInnes¹⁰, Alexis Ogdie¹¹, Dennis McGonagle¹², Christopher Ritchlin¹³, Nuala Brennan¹⁴, Ben Porter-Brown¹⁴, Eva Cullen¹⁴, Matthew R. Thomas¹⁴, Marius Albulescu¹⁴, Alex Godwood¹⁴, Kristian Reich¹⁵ and Laura Coates¹⁶, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France, ³Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁵Rheumatology, Immunology - Inflammation Medicine, University Hospital Goethe-University & Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany, ⁶Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ⁷University of Toronto, Toronto, ON, Canada, ⁸Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁹Department of Internal Medicine ³, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) & Universitätsklinikum Erlangen, Erlangen, Germany, ¹⁰University of Glasgow, Glasgow, United Kingdom, ¹¹University of Pennsylvania, Philadelphia, PA, ¹²Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, United Kingdom, ¹³University of Rochester Medical Center, Canandaigua, NY, ¹⁴MoonLake Immunotherapeutics AG, Zug, Switzerland, ¹⁵MoonLake Immunotherapeutics AG and Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Zug, Switzerland, ¹⁶Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom
Background/Purpose: Sonelokimab (SLK), a novel Nanobody that binds to both IL-17A and IL-17F with similarly high affinity, is designed to target difficult-to-reach sites of inflammation…
Abstract Number: 1382 • ACR Convergence 2025
Interstitial lung disease in primary sjögren syndrome: pathochrony, seronegative cases, and Risk of progressive pulmonary fibrosis
Delia Reina¹, Paula Estrada-Alarcón², Daniel Roig-Vilaseca¹, Dacia Cerdà¹, Vanessa Navarro-Angeles³, oscar Camacho¹, Sergi Herdia⁴, Marta lópez-Gómez¹, Silvia Gacía-Díaz¹, Paola Vidal Montal⁵, Pol Maymó-Paituvi⁶, martí Aguilar-Coll⁷ and Javier Narváez⁸, ¹Complex Hospitalari Universitari Moisès Broggi, Barcelona, Spain, ²Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ³Department of Rheumatology, Complex Universitari Hospitalari Moisès Broggi, Sant Joan Despí, Barcelona, Spain, Sant Joan Despí, Barcelona, Spain, ⁴Complex Hospitalari Moisès Broggi, Barcelona, Spain, ⁵Bellvitge University Hospital, Barcelona, Spain, ⁶Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ⁷Hospital Universitari de Bellvitge, Barcelona, Spain, ⁸Hospital Universitari de Bellvitge, L'Hospitalet; Barcelona, Barcelona, Spain
Background/Purpose: Sjögren’s disease (SjD) is a chronic autoimmune disorder primarily targeting exocrine glands. A significant extraglandular manifestation is interstitial lung disease (ILD), which contributes to…
Abstract Number: 1380 • ACR Convergence 2025
Phenotyping Neuropathic Pain in Sjögren’s Disease: A Cluster-Based Approach
Beatrice Dei¹, Stefano Donati¹, Gaetano La Rocca², Giovanni Fulvio¹, Federico Fattorini¹, Antonello Sulis¹, Michele Moretti¹, Elena Elefante¹, Francesco Ferro³, Giulia Ricci⁴, Marta Mosca⁵ and Chiara Baldini⁵, ¹Rheumatology Unit, University of Pisa, Pisa, Toscana, Italy, ²University of Pisa, Rheumatology Unit, Pisa, Pisa, Italy, ³Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, ⁴Neurology Unit, University of Pisa, Pisa, Toscana, Italy, ⁵University of Pisa, Pisa, Pisa, Italy
Background/Purpose: Neuropathic pain (NeP) is increasingly recognized as a relevant symptom domain in primary Sjögren’s disease (SjD), contributing to the disease burden beyond glandular involvement.…
Abstract Number: 1442 • ACR Convergence 2025
Modulation of Soluble Biomarkers of Cartilage and Bone Turnover and Inflammation by Zasocitinib (TAK-279), an Oral, Allosteric, Highly Selective and Potent TYK2 Inhibitor, is Associated with Clinical Response in Patients with Active Psoriatic Arthritis
Amit Choudhury¹, Jie Cheng², Feng Hong¹, Sachin Kumar¹, Ayumu Sugiura³, Jay Tang¹, Banishree Saha¹, Vinayagam Arunachalam³, Ting Hong³, Elena Tomaselli Muensterman¹, Haakan Wennbo³, Paresh Thakker¹ and Iain McInnes⁴, ¹Takeda Development Center Americas, Inc.,, Cambridge, MA, ²Takeda Development Center Americas, Inc., Cambridge, MA, ³Takeda Development Center Americas, Inc, Cambridge, MA, ⁴University of Glasgow, Glasgow, United Kingdom
Background/Purpose: As a chronic inflammatory disease, PsA is marked by cartilage and bone turnover and articular inflammation. Accordingly, elevated levels of inflammation and bone metabolism…
Abstract Number: 1256 • ACR Convergence 2025
Quantitative Analysis of a Pilot Study: Integrating Behavioral Health Services for Patients with Rheumatic Diseases
Shannon Teaw¹, Jessica Link-Malcolm², Michelle Ghebranious Farag³, Dorothy Patterson², Jenny Foster⁴, Sofia Bereket², Urooj Wahid², Puneet Bajaj², Elizabeth Solow², Jennifer Barton⁵ and Una Makris⁶, ¹UT Southwestern Medical School, Dallas, TX, ²UT Southwestern Medical Center, Dallas, TX, ³McGovern Medical School at UT Houston, Houston, TX, ⁴UT Southwestern Medical Center, Dallas, ⁵VA Portland Health Care System/OHSU, Portland, OR, ⁶UT Southwestern Medical Center and Dallas VA, Dallas, TX
Background/Purpose: Patients with rheumatic diseases (RD) often experience chronic pain, along with comorbid depression and anxiety, which can be addressed using behavioral health (BH) interventions…
Abstract Number: 1426 • ACR Convergence 2025
Understanding the Drivers of BASDAI and Back Pain Scores in Psoriatic Arthritis
Pankti Mehta¹, Fadi Kharouf², Virginia Carrizo Abarza³, Shangyi Gao⁴, Dafna D. Gladman⁵, Vinod Chandran⁶ and Denis Poddubnyy⁷, ¹University of Toronto, Gladman Krembil Psoriatic Arthritis Research Program, Toronto, ON, Canada, ²University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ³University of Toronto, Toronto, ⁴Gladman-Krembil Psoriatic Arthritis Research Program, Centre for Prognosis Studies in the Rheumatic Diseases, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Ontario, Canada, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany
Background/Purpose: The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is the most commonly used tool to assess axial disease in psoriatic arthritis (PsA). However, five…
Abstract Number: 1470 • ACR Convergence 2025
Why Do Some Lupus Patients Skip Their Mycophenolate Mofetil? A Multi-Factorial Assessment of Patient Compliance
Nidaa Bukhari¹, Ali Rizvi¹, Jian sun¹, Zerai Manna², Paul Schaughency³, Suraj Rajasimhan⁴ and Sarfaraz Hasni¹, ¹National Institutes of Health, BETHESDA, MD, ²NIH, Bethesda, MD, ³NIAID, NIH, Bethesda, MD, ⁴National Institutes of Health, Columbia, MD
Background/Purpose: Nonadherence to medication is a significant confounder in assessing treatment efficacy for systemic lupus erythematosus (SLE), with rates reported up to 75% depending on…
Abstract Number: 1028 • ACR Convergence 2025
Enhanced Assessment of Psoriatic Arthritis Disease Progression Using cDAPSA plus the Contrast of Patient Reported Pain and Global Assessment versus Joint Counts
Ning Meng¹, Scott Zeger², John Miller¹, Uzma Haque³, Thomas Grader-Beck⁴, Laura Hummers⁵, Clifton Bingham¹, Ami Shah⁵, Ana-Maria Orbai⁶ and Ji Soo Kim⁷, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins Biostatistics, Baltimore, MD, ³Johns Hopkins School of Medicine, Baltimore, MD, ⁴Johns Hopkins, Reisterstown, MD, ⁵Johns Hopkins Rheumatology, Baltimore, MD, ⁶Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Johns Hopkins, Baltimore, MD
Background/Purpose: The clinical Disease Activity in Psoriatic Arthritis (cDAPSA) score is widely used to assess PsA disease activity and its trajectory. cDAPSA sums four measures:…
Abstract Number: 1443 • ACR Convergence 2025
Long-Term Safety and Efficacy of Upadacitinib in Patients With Psoriatic Arthritis: 5-Year Results From the Phase 3 SELECT-PsA 1 Study
Iain McInnes¹, Koji Kato², Marina Magrey³, Joseph Merola⁴, mitsumasa kishimoto⁵, Derek Haaland⁶, Ivan Lagunes⁷, Laura Coates⁸, Yanxi Liu⁹, Erin Mancl¹⁰, Bhumik Parikh¹¹ and Charles Phillips¹², ¹University of Glasgow, Glasgow, United Kingdom, ²Abbvie. Inc, North Chicago, IL, ³Case Western Reserve University School of Medicine/University Hospitals Cleveland, Richfield, OH, ⁴UT Southwestern Medical Center, Dallas, TX, ⁵Kyorin University School of Medicine, Tokyo, Japan, ⁶The Waterside Clinic, Oro Medonte, ON, Canada, ⁷Abbvie Inc, North Chicago, IL, ⁸Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ⁹Abbvie Inc, Florham Park, NJ, ¹⁰AbbVie, Chicago, IL, ¹¹AbbVie, Hillsborough Township, NJ, ¹²AbbVie Inc, Princeton, NJ
Background/Purpose: We evaluated safety and efficacy of upadacitinib (UPA) versus adalimumab (ADA) at week 260 (5-years) from the long-term extension of SELECT-PsA 1.Methods: Randomized patients…
Abstract Number: 1384 • ACR Convergence 2025
Systematic Review of Therapies for Central Nervous System Manifestations in Sjögren’s Disease
Ghaith Noaiseh¹, Arun Varadhachary², Katherine Hammitt³, Julie Frantsve-Hawley³, Paula Barreras Cortes⁴, Shamik Bhattacharyya⁵, E. Sherwood Brown⁶, Drew Carey⁷, Robert Fox⁸, Brent Goodman⁹, Thomas Grader-Beck¹⁰, Janet Lewis¹¹, Stephen Maitz¹², Steven Mandel¹³, Jenifer McCombe¹⁴, Astrid Rasmussen¹⁵, George Sarka¹⁶, Daniel Wallace¹⁷, Frederick Vivino¹⁸, Rochelle Zak¹⁹, Nancy Carteron²⁰, R Hal Scofield¹⁵ and Steven Carsons²¹, ¹University of Kansas Medical Center, Kansas City, KS, ²Washington University in St. Louis, St. Louis, MO, ³Sjogren's Foundation, Reston, VA, ⁴Cedars Sinai, Los Angeles, CA, ⁵Brigham and Women's Hospital, Malden, MA, ⁶UT Southwestern Medical Center, Dallas, TX, ⁷Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Rheumatology Clinic, San Diego, CA, ⁹HonorHealth, Scottsdale, AZ, ¹⁰Johns Hopkins, Reisterstown, MD, ¹¹University of Virginia, Charlottesville, VA, ¹²U.S. Department of Veterans Affairs, Coatesville, PA, ¹³Donald and Barbara Zucker School of Medicine and Hofstra/Northwell, Hempstead, NY, ¹⁴University of Alberta, Edmonton, AB, Canada, ¹⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶Cedars-Sinai Medical Center, Laguna Hills, CA, ¹⁷Cedars Sinai Medical Center, Studio City, CA, ¹⁸University of Pennsylvania, Bryn Mawr, PA, ¹⁹UCSF Health, San Francisco, CA, ²⁰University of California, Berkeley & San Francisco, Angwin, CA, ²¹NYU Long Island School of Medicine, Mineola, NY
Background/Purpose: Sjögren’s disease is recognized as a multifaceted autoimmune disease impacting almost any organ or body system. Of particular importance is the central nervous system…
Abstract Number: 1279 • ACR Convergence 2025
Whole Blood Gene Expression Defined Subgroups of Treatment Naïve Children and Adolescents with Childhood-onset Systemic Lupus Erythematosus.
Reagan Reid¹, Huayun Hou², Isha Datar², Daniela Dominguez³, Andrea Knight⁴, Deborah Levy⁵, Lawrence Ng⁶, Zhaoyu Ding², Michael Wilson², Lauren Erdman⁷, Eleanor Pullenayegum² and Linda Hiraki⁵, ¹The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ²SickKids Research Institute, Toronto, ON, Canada, ³The Hospital for Sick Children, Toronto, Canada, ⁴Hospital for Sick Children, Toronto, ON, Canada, ⁵The Hospital for Sick Children, Toronto, ON, Canada, ⁶The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada, ⁷University of Cincinnati, Cincinnati, OH
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) is a clinically and genetically heterogeneous disease. We aimed to define subgroups of new diagnosis patients based on treatment…
Abstract Number: 1441 • ACR Convergence 2025
Efficacy and Safety of Vunakizumab in Patients with Active Ankylosing Spondylitis by Cigarette Smoking Status: A Post Hoc Analysis of a Randomized, Double-blind, Phase 2/3 Study
Hongbin Li¹ and Huilin Li², ¹Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Nei Mongol, China (People's Republic), ²Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China (People's Republic)
Background/Purpose: Vunakizumab, a humanized anti-interleukin-17A monoclonal antibody, has shown significant efficacy and favorable safety in patients with active ankylosing spondylitis (AS), leading to its approval…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].